Rose bengal

Last updated

Contents

Rose bengal
Rosebengalskeletal.png
Names
Preferred IUPAC name
4,5,6,7-Tetrachloro-3′,6′-dihydroxy-2′,4′,5′,7′-tetraiodo-3H-spiro[[2]benzofuran-1,9′-xanthen]-3-one
Other names
* C.I. 45440
  • C.I. Acid Red 94
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
ECHA InfoCard 100.021.813 OOjs UI icon edit-ltr-progressive.svg
EC Number
  • 223-993-4
PubChem CID
UNII
  • InChI=1S/C20H4Cl4I4O5/c21-9-7-8(10(22)12(24)11(9)23)20(33-19(7)31)3-1-5(25)15(29)13(27)17(3)32-18-4(20)2-6(26)16(30)14(18)28/h1-2,29-30H
    Key: IICCLYANAQEHCI-UHFFFAOYSA-N
  • O=C(O1)C2=C(C(Cl)=C(Cl)C(Cl)=C2Cl)C31C4=C(C(I)=C(O)C(I)=C4)OC5=C(I)C(O)=C(I)C=C53
Properties
C20H4Cl4I4O5
Molar mass 973.67 g/mol
1,017.65 g/mol (sodium salt)
Pharmacology
S01JA02 ( WHO )
Hazards
GHS labelling:
GHS-pictogram-exclam.svg
Warning
H315, H319, H335
P261, P264, P271, P280, P302+P352, P304+P340, P305+P351+P338, P312, P321, P332+P313, P337+P313, P362, P403+P233, P405, P501
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
X mark.svgN  verify  (what is  Yes check.svgYX mark.svgN ?)
Rose bengal solid and solution in water Bengal'skaia roza.jpg
Rose bengal solid and solution in water

Rose bengal (4,5,6,7-tetrachloro-2',4',5',7'-tetraiodofluorescein) is a stain. Rose bengal belongs to the class of organic compounds called xanthenes. [1] Its sodium salt is commonly used in eye drops to stain damaged conjunctival and corneal cells and thereby identify damage to the eye. The stain is also used in the preparation of Foraminifera for microscopic analysis, allowing the distinction between forms that were alive or dead at the time of collection.

A form of rose bengal is also being studied as a treatment for certain cancers and skin conditions. The cancer formulation of the drug, known as PV-10, is currently undergoing clinical trials for melanoma, [2] breast cancer. [3] and neuroendocrine tumors. The company also has formulated a drug based on rose bengal for the treatment of eczema and psoriasis; this drug, PV-10, is currently in clinical trials as well. [2]

History and etymology

Rose bengal was originally prepared in 1882 by Swiss chemist Robert Ghnem, as an analogue of fluorescein. [4] Rudolf Nietzki at the University of Basel identified the principal constituents of rose bengal as iodine derivatives of di- and tetra-chlorofluorescein. [5] The compound was originally used as a wool dye. [6] Its name derives from rose (flower) and Bengal (region); it is printed as rose bengal or Rose Bengal in the scientific literature. [7]

Chemical applications

Optical microscopy image of the undescribed species of Spinoloricus from Loricifera stained with rose bengal. Spinoloricus.png
Optical microscopy image of the undescribed species of Spinoloricus from Loricifera stained with rose bengal.

Despite its complicated photochemistry involving several species, [8] rose bengal is also used in synthetic chemistry as a visible light photoredox catalyst [9] and to generate singlet oxygen from triplet oxygen. The singlet oxygen can then undergo a variety of useful reactions, particularly [2 + 2] cycloadditions with alkenes and similar systems.

Derivatives and salts

Rose bengal can be used to form many derivatives that have important medical functions. One such derivative was created so to be sonosensitive but photoinsensitive, so that with a high intensity focused ultrasound, it could be used in the treatment of cancer. The derivative was formed by amidation of rose bengal, which turned off the fluorescent and photosensitive properties of rose bengal, leading to a usable compound, named in the study as RB2. [10]

rose bengal disodium salt Rose bengal sodium salt structure.png
rose bengal disodium salt

Salts of rose bengal include C20H2Cl4I4Na2O5 (CAS 632-69-9). This sodium salt is a dye, which has its own unique properties and uses. [11]

Biological applications

Before Brucella Rose Bengal Test application Rose Bengal Deneyi oncesi.jpg
Before Brucella Rose Bengal Test application
After Brucella Rose Bengal Test application Rose Bengal Deneyi.jpg
After Brucella Rose Bengal Test application

PV-10 (an injectable form of rose bengal) was found to cause an observable response in 60% of tumors treated, according to researchers in a phase II melanoma study. Locoregional disease control was observed in 75% of patients. Also confirmed was a "bystander effect", previously observed in the phase I trial, whereby untreated lesions responded to treatment as well, potentially due to immune system response. These data were based on the interim results (in 2009) of the first 40 patients treated in an 80-patient study. [3] [ needs update ]As of April 2016 a phase-3 study of PV-10 as a single agent therapy for patients with locally advanced cutaneous melanoma (Clinical Trials ID NCT02288897) is enrolling patients. [2]

Rose bengal has been shown to not just prevent the growth and spread of ovarian cancer, but also to cause apoptotic cell death of the cancer cells. This has been proven in vitro, in order to prove that rose bengal is still a possible option in the treatment of cancer, and further research should be done. [12]

Rose bengal has been used to treat colon cancer. In one such study, [13] a protective immune response was generated from immunogenic cell death.

Rose bengal is also used in animal models of ischemic stroke (photothrombotic stroke models) in biomedical research. A bolus of the compound is injected into the venous system. Then the region of interest (e.g., the cerebral cortex) is exposed and illuminated by LASER light of 561 nm. A thrombus is formed in the illuminated blood vessels, causing a stroke in the dependent brain tissue. [14] [15]

Rose bengal has been used for 50 years to diagnose liver and eye cancer. Rose bengal dye is mixed with the homogenate of Brucella and pH of the solution is maintained at 3.8, and this dye is used to diagnose Brucellosis by agglutinating the suspected serum. Rose bengal is slightly irritating and toxic to the eye. [6] It has also been used as an insecticide. [16] [17]

Rose bengal is able to stain cells whenever the surface epithelium is not being properly protected by the preocular tear film, because rose bengal has been proven to not be able to stain cells because of the protective functioning of these preocular tear films. [18] This is why rose bengal is often useful as a stain in diagnosing certain medical issues, such as conjunctival and lid disorders. [19]

Rose bengal has been used for ocular surface staining to study the efficacy of punctal plugs in the treatment of keratoconjunctivitis sicca. [20]

Rose bengal is being researched as an agent in creating nano sutures. [21] Wounds are painted on both sides with it and then illuminated with an intense light. This links the tiny collagen fibers together sealing the wound. [22] [23] [24] Healing is faster and the seal reduces chances of infection. [25] [26]

Rose bengal is used to suppress bacterial growth in several microbiological media, including Cooke's rose bengal agar.

Rose bengal has been used as a protoplasm stain to discriminate between living and dead micro-organisms, particularly Foraminifera, since the 1950s when Bill Walton developed the technique. [27]

Rose bengal acetate can act as a photosensitiser and may have potential in photodynamic therapy to treat some cancers. [28]

Related Research Articles

Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system. Immunotherapies designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies. Immunotherapy is under preliminary research for its potential to treat various forms of cancer.

<span class="mw-page-title-main">Photodynamic therapy</span> Form of phototherapy

Photodynamic therapy (PDT) is a form of phototherapy involving light and a photosensitizing chemical substance used in conjunction with molecular oxygen to elicit cell death (phototoxicity).

<span class="mw-page-title-main">Basal-cell carcinoma</span> Most common type of skin cancer

Basal-cell carcinoma (BCC), also known as basal-cell cancer, basalioma or rodent ulcer, is the most common type of skin cancer. It often appears as a painless raised area of skin, which may be shiny with small blood vessels running over it. It may also present as a raised area with ulceration. Basal-cell cancer grows slowly and can damage the tissue around it, but it is unlikely to spread to distant areas or result in death.

<span class="mw-page-title-main">Light therapy</span> Therapy involving intentional exposure to sunlight

Light therapy, also called phototherapy or bright light therapy is the exposure to direct sunlight or artificial light at controlled wavelengths in order to treat a variety of medical disorders, including seasonal affective disorder (SAD), circadian rhythm sleep-wake disorders, cancers, and skin wound infections. Treating skin conditions such as neurodermatitis, psoriasis, acne vulgaris, and eczema with ultraviolet light is called ultraviolet light therapy.

<span class="mw-page-title-main">Melanoma</span> Skin cancer originating in melanocytes

Melanoma is the most dangerous type of skin cancer; it develops from the melanin-producing cells known as melanocytes. It typically occurs in the skin, but may rarely occur in the mouth, intestines, or eye.

A cancer vaccine, or oncovaccine, is a vaccine that either treats existing cancer or prevents development of cancer. Vaccines that treat existing cancer are known as therapeutic cancer vaccines or tumor antigen vaccines. Some of the vaccines are "autologous", being prepared from samples taken from the patient, and are specific to that patient.

<span class="mw-page-title-main">Cancer immunotherapy</span> Artificial stimulation of the immune system to treat cancer

Cancer immunotherapy (immuno-oncotherapy) is the stimulation of the immune system to treat cancer, improving the immune system's natural ability to fight the disease. It is an application of the fundamental research of cancer immunology (immuno-oncology) and a growing subspecialty of oncology.

An oncolytic virus is a virus that preferentially infects and kills cancer cells. As the infected cancer cells are destroyed by oncolysis, they release new infectious virus particles or virions to help destroy the remaining tumour. Oncolytic viruses are thought not only to cause direct destruction of the tumour cells, but also to stimulate host anti-tumour immune system responses. Oncolytic viruses also have the ability to affect the tumor micro-environment in multiple ways.

<span class="mw-page-title-main">Targeted therapy</span> Type of therapy

Targeted therapy or molecularly targeted therapy is one of the major modalities of medical treatment (pharmacotherapy) for cancer, others being hormonal therapy and cytotoxic chemotherapy. As a form of molecular medicine, targeted therapy blocks the growth of cancer cells by interfering with specific targeted molecules needed for carcinogenesis and tumor growth, rather than by simply interfering with all rapidly dividing cells. Because most agents for targeted therapy are biopharmaceuticals, the term biologic therapy is sometimes synonymous with targeted therapy when used in the context of cancer therapy. However, the modalities can be combined; antibody-drug conjugates combine biologic and cytotoxic mechanisms into one targeted therapy.

<span class="mw-page-title-main">Uveal melanoma</span> Type of eye cancer

Uveal melanoma is a type of eye cancer in the uvea of the eye. It is traditionally classed as originating in the iris, choroid, and ciliary body, but can also be divided into class I and class II. Symptoms include blurred vision, loss of vision, and photopsia, but there may be no symptoms.

<span class="mw-page-title-main">Steven Rosenberg</span> American cancer researcher

Steven A. Rosenberg is an American cancer researcher and surgeon, chief of Surgery at the National Cancer Institute in Bethesda, Maryland and a Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Sciences. He pioneered the development of immunotherapy that has resulted in the first effective immunotherapies and the development of gene therapy. He is the first researcher to successfully insert foreign genes into humans.

<span class="mw-page-title-main">PAC-1</span> Chemical compound

PAC-1 is a synthesized chemical compound that selectively induces apoptosis, in cancerous cells. It was granted orphan drug status by the FDA in 2016.

<span class="mw-page-title-main">Tumor-infiltrating lymphocytes</span>

Tumor-infiltrating lymphocytes (TIL) are white blood cells that have left the bloodstream and migrated towards a tumor. They include T cells and B cells and are part of the larger category of ‘tumor-infiltrating immune cells’ which consist of both mononuclear and polymorphonuclear immune cells, in variable proportions. Their abundance varies with tumor type and stage and in some cases relates to disease prognosis.

Oral pigmentation is asymptomatic and does not usually cause any alteration to the texture or thickness of the affected area. The colour can be uniform or speckled and can appear solitary or as multiple lesions. Depending on the site, depth, and quantity of pigment, the appearance can vary considerably.

<span class="mw-page-title-main">Cancer treatment</span> Overview of various treatment possibilities for cancer

Cancer treatments are a wide range of treatments available for the many different types of cancer, with each cancer type needing its own specific treatment. Treatments can include surgery, chemotherapy, radiation therapy, hormonal therapy, targeted therapy including small-molecule drugs or monoclonal antibodies, and PARP inhibitors such as olaparib. Other therapies include hyperthermia, immunotherapy, photodynamic therapy, and stem-cell therapy. Most commonly cancer treatment involves a series of separate therapies such as chemotherapy before surgery. Angiogenesis inhibitors are sometimes used to enhance the effects of immunotherapies.

Adoptive cell transfer (ACT) is the transfer of cells into a patient. The cells may have originated from the patient or from another individual. The cells are most commonly derived from the immune system with the goal of improving immune functionality and characteristics. In autologous cancer immunotherapy, T cells are extracted from the patient, genetically modified and cultured in vitro and returned to the same patient. Comparatively, allogeneic therapies involve cells isolated and expanded from a donor separate from the patient receiving the cells.

Racotumomab is a therapeutic cancer vaccine for the treatment of solid tumors that is currently under clinical development by ReComBio, an international public-private consortium with the participation of the Center of Molecular Immunology at Havana, Cuba (CIM) and researchers from Buenos Aires University and National University of Quilmes in Argentina. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival.

<span class="mw-page-title-main">Nivolumab</span> Anticancer medication

Nivolumab, sold under the brand name Opdivo, is an anti-cancer medication used to treat a number of types of cancer. This includes melanoma, lung cancer, malignant pleural mesothelioma, renal cell carcinoma, Hodgkin lymphoma, head and neck cancer, urothelial carcinoma, colon cancer, esophageal squamous cell carcinoma, liver cancer, gastric cancer, and esophageal or gastroesophageal junction cancer. It is administered intravenously.

<span class="mw-page-title-main">Talimogene laherparepvec</span> Gene therapy medication

Talimogene laherparepvec, sold under the brand name Imlygic among others, is a biopharmaceutical medication used to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the recipient's cancer. The final four year analysis from the pivotal phase 3 study upon which TVEC was approved by the FDA showed a 31.5% response rate with a 16.9% complete response (CR) rate. There was also a substantial and statistically significant survival benefit in patients with earlier metastatic disease and in patients who hadn't received prior systemic treatment for melanoma. The earlier stage group had a reduction in the risk of death of approximately 50% with one in four patients appearing to have met, or be close to be reaching, the medical definition of cure. Real world use of talimogene laherparepvec have shown response rates of up to 88.5% with CR rates of up to 61.5%.

<span class="mw-page-title-main">Cellular adoptive immunotherapy</span> Immunotherapy using T-cells

Cellular adoptive immunotherapy is a type of immunotherapy. Immune cells such as T-cells are usually isolated from patients for expansion or engineering purposes and reinfused back into patients to fight diseases using their own immune system. A major application of cellular adoptive therapy is cancer treatment, as the immune system plays a vital role in the development and growth of cancer. The primary types of cellular adoptive immunotherapies are T cell therapies. Other therapies include CAR-T therapy, CAR-NK therapy, macrophage-based immunotherapy and dendritic cell therapy.

References

  1. "Rose Bengal Compound Summary". PubChem.
  2. 1 2 3 Provectus Biopharmaceuticals Reports Data On PV-10 in Combination Therapy and T Cell Mediated Immunity Presented at American Association for Cancer Research (AACR) Annual Meeting 2016. April 2016
  3. 1 2 Metastatic Melanoma PV-10 Trial Results Encouraging Says Drug Company, Medical News Today, 9 June 2009
  4. Alexander W (2010). "American Society of Clinical Oncology, 2010 Annual Meeting and Rose Bengal: From a Wool Dye to a Cancer Therapy". Pharmacy and Therapeutics. 35 (8): 469–474. PMC   2935646 . PMID   20844697.
  5. Orellana C. "Rose Bengal The pink eye stain that might be a cancer treatment".
  6. 1 2 Orellana C. "Rose Bengal--the Pink Eye Stain that might be a Cancer Treatment".
  7. Senning, Alexander (2006). Elsevier's Dictionary of Chemoetymology: The Whys and Whences of Chemical Nomenclature and Terminology. Elsevier. p. 344. ISBN   978-0-08-048881-3.
  8. Ludvíková L, Friš P, Heger D, Šebej P, Wirz J, Klán P (2016). "Photochemistry of rose bengal in water and acetonitrile: a comprehensive kinetic analysis". Physical Chemistry Chemical Physics. 18 (24): 16266–16273. Bibcode:2016PCCP...1816266L. doi:10.1039/C6CP01710J. ISSN   1463-9076. PMID   27253480.
  9. Romero NA, Nicewicz DA (2016-09-14). "Organic Photoredox Catalysis". Chemical Reviews. 116 (17): 10075–10166. doi:10.1021/acs.chemrev.6b00057. ISSN   0009-2665. PMID   27285582.
  10. Kim Y, Valentina Rubio, Jianjun Qi, Rongmin Xia, Zheng-Zheng Shi, Leif Peterson, Ching-Hsuan Tung, Brian E. O'Neill (2012). "Cancer treatment using an optically inert rose bengal derivative combined with pulsed focused ultrasound". AIP Conference Proceedings. 1481 (1): 175. Bibcode:2012AIPC.1481..175K. doi:10.1063/1.4757330. Published as Kim YS, Rubio V, Qi J, Xia R, Shi ZZ, Peterson L, Tung CH, O'Neill BE (2011). "Cancer treatment using an optically inert Rose Bengal derivative combined with pulsed focused ultrasound". J Control Release. 156 (3): 315–22. doi:10.1016/j.jconrel.2011.08.016. PMC   3230682 . PMID   21871506.
  11. "Rose Bengal Sodium Salt". Sigma-Aldrich. Sigma Aldrich Co. Retrieved 12 November 2013.
  12. Koevary S (2012). "Selective toxicity of rose bengal to ovarian cancer cells in vitro". International Journal of Physiology, Pathophysiology and Pharmacology. 4 (2): 99–107. PMC   3403562 . PMID   22837809.
  13. Qin J (2017). "Colon cancer cell treatment with rose bengal generates a protective immune response via immunogenic cell death". Cell Death and Disease. 8 (2): e2584. doi:10.1038/cddis.2016.473. PMC   5386459 . PMID   28151483.
  14. Salber D, et al. (2006). "Differential uptake of [18F]FET and [3H]l-methionine in focal cortical ischemia". Nuclear Medicine and Biology. 33 (8): 1029–1035. doi:10.1016/j.nucmedbio.2006.09.004. PMID   17127177.
  15. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD (1985). "Induction of reproducible brain infarction by photochemically initiated thrombosis". Ann Neurol. 17 (5): 497–504. doi:10.1002/ana.410170513. PMID   4004172. S2CID   37827695.
  16. Capinera JL, Squitier JM (2000). "Insecticidal Activity of Photoactive Dyes to American and Migratory Grasshoppers (Orthoptera: Acrididae)". Journal of Economic Entomology. 93 (3): 662–666. doi:10.1603/0022-0493-93.3.662. PMID   10902313. S2CID   25514306.
  17. Martin P, Mischke S, Schroder R (1998). "Compatibility of Photoactive Dyes with Insect Biocontrol Agents". Biocontrol Science and Technology. 8 (4): 501–508. Bibcode:1998BioST...8..501M. doi:10.1080/09583159830018.
  18. Feenstra R, Tseng, S (July 1992). "What is actually stained by rose bengal?". Arch Ophthalmol. 110 (7): 984–993. doi:10.1001/archopht.1992.01080190090035. PMID   1637285.
  19. Yokoi N (2012). "Vital staining for disorders of conjunctiva and lids". Atarashii Ganka. 29: 1599–1605.
  20. Ervin AM, Wojciechowski R, Schein O (June 26, 2017). "Punctal occlusion for dry eye syndrome". Cochrane Database Syst Rev. 9 (6): CD006775. doi:10.1002/14651858.CD006775.pub3. PMC   5568656 . PMID   28649802.
  21. Chan B, Chan O, So K (2008). "Effects of photochemical crosslinking on the microstructure of collagen and a feasibility study on controlled protein release". Acta Biomaterialia. 4 (6): 1627–1636. doi:10.1016/j.actbio.2008.06.007. PMID   18640085.
  22. O’Neill A.C., Winograd J.M, Zeballos J.M., Johnson T.S., Randolph M.A., Bujold K.E., Kochevar I.E., Redmond R.W. (2007). "Microvascular anastomosis using a photochemical tissue bonding technique". Lasers in Surgery and Medicine. 39 (9): 716–722. doi:10.1002/lsm.20548. PMID   17960755. S2CID   46712914.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  23. Mulroy L., Kim J., Wu I., Scharper P., Melki S.A., Azar D.A., Redmond R.W., Kochevar I.E. (2000). "Photochemical keratodesmos for repair of lamellar corneal incisions". Invest Ophthalmol Vis Sci. 41 (11): 3335–3340. PMID   11006222.
  24. Proano C.E., Mulroy L., Erika Jones E., Azar D.A., Redmond R.W., Kochevar I.E. (2004). "Characterization of paracellular penetration routes". Invest Ophthalmol Vis Sci. 38 (11): 2177–2181. PMID   9344340.
  25. Laser Show in the Surgical Suite, Technology Review, March/April 2009
  26. Laser Show in the Surgical Suite, Technology Review, 02.11.2009
  27. Walton W (1952). "Techniques for recognition of living foraminifera". Contrib. Cushman Found. Foraminiferal Res. 3: 56–60.
  28. Panzarini E, Inguscio V, Fimia GM, Dini L (2014). "Rose Bengal acetate photodynamic therapy (RBAc-PDT) induces exposure and release of Damage-Associated Molecular Patterns (DAMPs) in human HeLa cells". PLOS ONE. 9 (8): e105778. Bibcode:2014PLoSO...9j5778P. doi: 10.1371/journal.pone.0105778 . PMC   4139382 . PMID   25140900.